This is followed by a sophisticated two-step MR analysis employing an array of 92 inflammatory biomarkers to unravel the potential pathways through which SGLT-2 inhibitors exert their influence on HF risk, thereby augmenting our understanding of the inflammatory underpinnings related to the cardiac benefit of SGLT-2 inhibitors. This evidence concerns the gene SLC5A2 and hydrops fetalis.